Post-progression survival and progression-free survival in patients with advanced hepatocellular carcinoma treated by sorafenib

フォーマット:

論文

責任表示:

Terashima, Takeshi ; Yamashita, Tatsuya ; Takata, Noboru ; Nakagawa, Hidetoshi ; Toyama, Tadashi ; Arai, Kuniaki ; Kitamura, Kazuya ; Yamashita, Taro ; Sakai, Yoshio ; Mizukoshi, Eishiro ; Honda, Masao ; Kaneko, Shuichi

言語:

英語

出版情報:

Blackwell Publishing Ltd., 2016-06-01

著者名:

Terashima, Takeshi

Yamashita, Tatsuya

Takata, Noboru

Nakagawa, Hidetoshi

Toyama, Tadashi

Arai, Kuniaki

Kitamura, Kazuya

Yamashita, Taro

Sakai, Yoshio

Mizukoshi, Eishiro

Honda, Masao

Kaneko, Shuichi

続きを見る

掲載情報:

Hepatology Research

ISSN:

1386-6346      

巻:

46

通号:

7

開始ページ:

650

終了ページ:

656

バージョン:

author

概要:

Aim: Although sorafenib is a standard drug for advanced hepatocellular carcinoma (HCC), little is known about a patient's clinical course after treatment. We investigated the effect of post-progression survival (PPS) and progression-free survival (PFS) on overall survival (OS) in patients whose advanced HCC was treated by sorafenib. Methods: We searched in the PubMed database for reports with survival data of patients with HCC treated with … sorafenib monotherapy, and selected reports with 20 or more patients each that provided data for both OS and PFS or time to progression (TTP). Median PPS (mPPS) was defined as the period obtained by subtracting median PFS or TTP (mPFS/TTP) from median OS (mOS). We identified 56 reports with 5803 patients. We investigated the correlation of mOS and either mPPS or mPFS/TTP using weighted linear regression. Results: Median PPS correlated with mOS (r=0.834) very strongly, whereas mPFS/TTP did not correlate with mOS as highly as PPS did (r=0.546). When we stratified survival data by Child-Pugh classification, a significantly greater average percentage of mPPS to mOS was seen in Child-Pugh class A (54.4±17.6%) than in Child-Pugh class B (32.0±11.6%) (P=0.015). Conclusion: PPS highly correlated with OS, and its importance should be more emphasized for advanced HCC patients treated after sorafenib therapy, whereas we need to take more care in interpreting the results of PFS to evaluate treatment efficacy in clinical trials of advanced HCC. © 2015 The Japan Society of Hepatology.<br />Embargo Period 12 months 続きを見る

URL:

http://hdl.handle.net/2297/44240